The Food and Drug Administration (FDA) said on July 12, 2019, that it was “expediting” its efforts to develop rules for cannabidiol (CBD) and plans to issue a report on the department’s progress by early fall, its acting chief information officer announced on Twitter.

FDA Acting Chief Information Officer Amy Abernethy tweeted that “FDA is expediting its work to address the many questions about cannabidiol (CBD),” describing it as “an important national issue with public health impact.”

Read the full article at